Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule

Nuclear Medicine Communications

Volumn 30, Issue 2, 2009, Pages 169-175

  Zakavi, Seyed Rasoul ^a,b   Mousavi, Zohreh ^a   Davachi, Behroze ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Radioiodine; Thyroid nodule; Thyrotoxicosis; Toxic adenoma

Indexed keywords

IODINE 131; PERTECHNETIC ACID TC 99M; THIAMAZOLE; THYROTROPIN;

ADULT; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THYROID ADENOMA; THYROID NODULE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOPHARMACEUTICALS; THYROID NODULE; TREATMENT OUTCOME;

EID: 58549100130     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283169148     Document Type: Article

References (28)

1. Blum M, Shenkman L, Hollander CS. The autonomous nodule of the thyroid. Correlation of patient age, nodule size and functional status. Am J Med Sci 1975; 269:43-50.
2. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501-509.
3. Nayak B, Hodak SP. Hyperthyroidism. Endocrinol Metab Clin N Am 2007; 36:617-656.
4. Gurleyik E, Pahlivan M, Gokpinar I. Surgery is the procedure of choice for the treatment of patients with toxic adenoma in an endemic goiter area. Acta Chir Belg 2005; 105:373-377.
5. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330:1731.
6. Iagraru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med 2007; 48:379-389.
7. Tondeur M, Gilnoer D, Sand A, Vereist J, Ham H. Variability of the administered radioiodine doses for the treatment of hyperthyroidism in Belgium. Clin Endocrinol (Oxf) 2006; 65:206-209.
8. Tzavara I, Tzanela M, Vlassopoulou B, Kouyiomoutzakis G, Kyriazopoulou V, Alevizaki C, Thalassinos NC. Long term thyroid function after (131)1 treatment for toxic adenoma. Hormones (Athens) 2002; 1:99-103.
9. Huysmans DA, Hermus AR, Corstens FH, Kloppenborg PW. Long term results of two schedules of radioiodine treatment for toxic multinodular goiter. Eur J Nucl Med Mol Imaging 2006; 33:608-612.
10. Huysmans DA, Corstens FH, Kloppenborg PW. Long-term follow up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med 1991; 32:27-39.
11. Mousavi Z, Zakavi SR. The optimal time of discontinuing Methimazole before radio-iodine therapy. Iran J Nucl Med 2001; 14-15:29-32.
12. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Grave's hyperthyroidism. J Clin Endocrinol Metab 2003; 88:978-983.
13. Duprez L, Parma J, Van Sande J, Rodien P, Sabine C, Abramowicz M, et al. Pathology of the TSH receptor. J Pediatr Endocrinol Metab 1999; 84:4155-4158.
14. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision-a cost effectiveness analysis. Thyroid 2004; 14:933-945.
15. Hamburger JL The autonomously functioning thyroid nodule: Goetsch's disease. Endocr Rev 1987; 8:439-447.
16. Hennemann G. Autonomously functioning thyroid nodules and other causes of thyrotoxicosis. In: DeGroot LJ, Jumeson JL, editors. Endocrinology. Philadelphia: Saunders Elsevier; 2006. pp. 2043-2053.
17. Van Isselt JW, Van Dongen AJ. The current status of radio-iodine therapy for benign thyroid disorders. Hell J Nucl Med 2004; 7:104-110.
18. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86:3611-3617.
19. Zakavi SR, Mousavi Z. Effect of multiple factors on success rate of high dose radioiodine therapy (>150μCi/gr) in 164 patients with hyperthyroidism. Iran J Nucl Med 2000; 12-13:48-53.
20. Vemulakonda US, Atkins FB, Ziessman HA. Therapy dose calculations in Graves' disease using early 1-123 uptake measurements. Clin Nucl Med 1996; 21:102-105.
21. Zingrillo M, Urbano N, Suriano V, Modoni S. Radioiodine treatment of Plummer and multinodular toxic and nontoxic goiter disease by the first approximation dosimetry method. Cancer Biother Radiopharm 2007; 22:256-260.
22. Meier DA, Dworkin HJ. The autonomously functioning thyroid nodule. J Nucl Med 1991; 32:30-32.
23. Erdogan MF, Kucuk NO, Anil G, Aras S, Ozer D, Aras G, et al. Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenoma. Nucl Med Commun 2004; 25:1083-1087.
24. Reschini E, Matheoud R, Canzi C, Castellani M, Galelli M, Ferrari C, et al. Dosimetry study in patients with autonomous thyroid nodule who are candidates for radioiodine therapy. J Nucl Med 1999; 40: 1928-1934.
25. 131I. N Engl J Med 1983; 309:1473-1476.
26. Marin JF, Marana G, Salto L, Astigarraga B, Esterada FJ, Lucas T, et al. Treatment of solitary toxic nodule with 1-131: results in 43 patients. Med Clin (Bare) 1991; 96:730-732 (Abstract).
27. Tarantini B, Ciuoli C, Di Cairano G, Guarino E, Mazzucato P, Montanaro A, et al. Effectiveness of radioiodine(131-I) as definitive therapy in patients with autoimmune and nonautoimmune hyperthyroidism. J Endocrine/ Invest 2006; 29:594-598.
28. Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann Intern Med 1984; 101:488-490.